Sonnet Research And Ddevelopement To Revenue from 2010 to 2024
| SONN Stock | USD 2.63 0.14 5.05% |
Research And Ddevelopement To Revenue | First Reported 2010-12-31 | Previous Quarter 0.00503415 | Current Value 0.004782 | Quarterly Volatility 26.12882273 |
Check Sonnet Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonnet Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.4 M or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or PTB Ratio of 5.12. Sonnet financial statements analysis is a perfect complement when working with Sonnet Biotherapeutics Valuation or Volatility modules.
Sonnet | Research And Ddevelopement To Revenue |
Latest Sonnet Biotherapeutics' Research And Ddevelopement To Revenue Growth Pattern
Below is the plot of the Research And Ddevelopement To Revenue of Sonnet Biotherapeutics Holdings over the last few years. It is the ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services. Sonnet Biotherapeutics' Research And Ddevelopement To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sonnet Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research And Ddevelopement To Revenue | 10 Years Trend |
|
Research And Ddevelopement To Revenue |
| Timeline |
Sonnet Research And Ddevelopement To Revenue Regression Statistics
| Arithmetic Mean | 14.03 | |
| Geometric Mean | 0.21 | |
| Coefficient Of Variation | 186.23 | |
| Mean Deviation | 20.52 | |
| Median | 0.05 | |
| Standard Deviation | 26.13 | |
| Sample Variance | 682.72 | |
| Range | 79.9295 | |
| R-Value | 0.50 | |
| Mean Square Error | 552.61 | |
| R-Squared | 0.25 | |
| Significance | 0.06 | |
| Slope | 2.91 | |
| Total Sum of Squares | 9,558 |
Sonnet Research And Ddevelopement To Revenue History
About Sonnet Biotherapeutics Financial Statements
Sonnet Biotherapeutics investors utilize fundamental indicators, such as Research And Ddevelopement To Revenue, to predict how Sonnet Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year |
Pair Trading with Sonnet Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sonnet Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Sonnet Stock
| 0.73 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.9 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.89 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Sonnet Stock
| 0.9 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.82 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.53 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.43 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.39 | PHVS | Pharvaris BV | PairCorr |
The ability to find closely correlated positions to Sonnet Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sonnet Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sonnet Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sonnet Biotherapeutics Holdings to buy it.
The correlation of Sonnet Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sonnet Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sonnet Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sonnet Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Sonnet Biotherapeutics Correlation against competitors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.